However, PFS assessed by the independent review committee (secondary endpoint) failed to reach statistical significance (16.1 vs 12.3 months; HR 0.85; 95% CI 0.67 to 1.07; log-rank p=0.16).
← all excerpts
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
1
0.1600
0.1600